Skip to content

The effect of Citrus aurantium on vaginal atrophy

The effect of Citrus aurantium vaginal cream on vaginal atrophy in postmenopausal women

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200215046494N1
Enrollment
30
Registered
2020-03-22
Start date
2020-04-18
Completion date
Unknown
Last updated
2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal atrophy. Postmenopausal atrophic vaginitis

Interventions

Citrus aurantium vaginal cream 4%, one applicator every night for two weeks and then one night in between in later two-weeks.

Sponsors

Gonabad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
45 Years to 65 Years

Inclusion criteria

Inclusion criteria: Having amenorrhea for at least 12 months Age 45-65 years old Having sex with single spouse Normal Pap smear over the past 3 years Body mass index less than 30 Complaining of vaginal atrophy symptoms (vaginal burning, vaginal itching , Vaginal dryness and pain during intercourse) Getting a score of = 65 on the visual analogue scale (VAS) Having at least one symptom of vaginal mucosa descriptive evaluation table symptoms pH value > 5 Vaginal maturation value (VMV) < 50

Exclusion criteria

Exclusion criteria: Vaginal infection or any other important genital tract disease (sexually transmitted diseases) Excessive consumption of phytoestrogens such as soy, red clover, fenugreek and vitex during the 8 weeks prior to the study Use of hormone replacement therapy during the 8 weeks before the study A history of asthma and allergies to certain herbs or citrus fruits Use of vaginal drugs or any lubricant for at least 15 days prior to study Smoking, alcohol or any other drug Mammary mass Uterine bleeding or spotting Kidney Disorders, Kidney Failure, Hypertension, Thyroid Disorders, Liver Disorders, Heart Problems, Psychological problems and epilepsy Use of monoamine oxidase drugs, antidepressants, Antihypertensive drugs, thyroid medication, supplements and vitamins Prolapse of pelvic organs grade 3 or More

Design outcomes

Primary

MeasureTime frame
Vaginal acidity. Timepoint: Before and 2 and 4 weeks after intervention. Method of measurement: pH strip.;Vaginal maturation value. Timepoint: Before and 2 and 4 weeks after intervention. Method of measurement: Vaginal smear.;Subjective symptoms of vaginal atrophy. Timepoint: Before and 2 and 4 weeks after intervention. Method of measurement: Visual Analogue Scale.;Vaginal physical examination. Timepoint: Before and 2 and 4 weeks after intervention. Method of measurement: Vaginal physical examination checklist.

Secondary

MeasureTime frame
Quality of life. Timepoint: Before and 2 and 4 weeks after intervention. Method of measurement: Menopause quality of life questionnaire (MENQOL questionare).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahram Asgharpoor

Gonabad University of Medical Sciences

homeira_60@yahoo.com+98517223028

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026